Q2 2022 EPS Estimates for Compass Therapeutics, Inc. (OTC:CMPX) Raised by Analyst

Compass Therapeutics, Inc. (OTC:CMPXGet Rating) – Equities researchers at SVB Leerink boosted their Q2 2022 EPS estimates for shares of Compass Therapeutics in a note issued to investors on Monday, May 9th. SVB Leerink analyst A. Berens now expects that the company will post earnings of ($0.14) per share for the quarter, up from their previous forecast of ($0.16). SVB Leerink also issued estimates for Compass Therapeutics’ Q3 2022 earnings at ($0.11) EPS, FY2022 earnings at ($0.44) EPS, FY2023 earnings at ($0.76) EPS, FY2024 earnings at ($1.28) EPS, FY2025 earnings at ($1.53) EPS and FY2026 earnings at ($1.46) EPS.

Several other research firms have also recently weighed in on CMPX. HC Wainwright began coverage on shares of Compass Therapeutics in a report on Friday, January 21st. They set a “buy” rating and a $11.00 price target on the stock. LADENBURG THALM/SH SH began coverage on Compass Therapeutics in a research note on Tuesday, March 15th. They issued a “buy” rating and a $7.00 target price on the stock. B. Riley started coverage on Compass Therapeutics in a research report on Tuesday, January 18th. They set a “buy” rating and a $10.00 price target for the company. Finally, Zacks Investment Research lowered Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, April 4th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $8.91.

Shares of CMPX stock opened at $1.84 on Thursday. The firm has a 50-day moving average of $1.50 and a 200-day moving average of $2.10. Compass Therapeutics has a one year low of $1.25 and a one year high of $5.92.

A number of hedge funds have recently modified their holdings of the business. Difesa Capital Management LP bought a new position in Compass Therapeutics in the 4th quarter worth about $33,000. Millennium Management LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth about $35,000. Mirabella Financial Services LLP bought a new position in shares of Compass Therapeutics in the fourth quarter valued at approximately $60,000. JPMorgan Chase & Co. bought a new position in shares of Compass Therapeutics in the fourth quarter valued at approximately $75,000. Finally, New Capital Management LP purchased a new position in Compass Therapeutics during the fourth quarter valued at approximately $77,000. 66.04% of the stock is currently owned by institutional investors and hedge funds.

In other Compass Therapeutics news, CEO Thomas J. Schuetz purchased 27,836 shares of the stock in a transaction dated Tuesday, May 10th. The shares were bought at an average price of $1.80 per share, with a total value of $50,104.80. Following the completion of the transaction, the chief executive officer now directly owns 5,153,303 shares in the company, valued at approximately $9,275,945.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc purchased 90,712 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The shares were acquired at an average price of $1.56 per share, for a total transaction of $141,510.72. Following the completion of the purchase, the director now directly owns 14,601,031 shares in the company, valued at approximately $22,777,608.36. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 128,748 shares of company stock valued at $208,242.

About Compass Therapeutics (Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area.

See Also

Earnings History and Estimates for Compass Therapeutics (OTC:CMPX)

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.